Medical Health & Life Science Research News

New report examines the cancer drug market

Medical Market Research

The Global Cancer Drug market represents its costing, production, scope to increase its demand by 2018 - 2023 year. The Cancer Drug Market Report is based on Global key findings, Regional analysis, Growth factors and others. The Report helps to fasten the business across the globe and provides in-depth information.

Global Cancer Drug Market was valued at USD 73.41 Billion in the year 2017. Global Cancer Drug market is further estimated to grow at a CAGR of 7.98% from 2018 to 2023 to reach USD 116.39 Billion by the year 2023.

North America region holds the highest market share in 2017 with APAC region is considered as the fastest growing market in the forecasted period. At a country level, the U.S is the biggest market in 2017 and it is projected to grow at a gradual pace in the coming years.

Roche Diagnostics (Switzerland), Celgene (U.S), Johnson & Johnson (U.S) and Novartis (Switzerland) are some of the key manufacturers in the Global Blood Screening market. From all the key players Roche Diagnostics holds the substantial market share because of its better global presence both at production and at an operational level.

Rising research and development expenses to cater changing demand of end users, similarly, growth strategies such as acquisition, merger, and expansion of the distribution network were few techniques adopted by most of Tier 1 and Tier 2 manufacturers in recent years.

Report: goo.gl/9suaBr

Drivers

            Growing incidence and pervasiveness of various types of cancer

            Academic alliances and partnerships

Restrain

            Side-effects of anti-cancer drug therapy

            The high cost of drug development and a threat of failure

Opportunity

            Scientific advancements in treatment methods

            Increasing focus on personalized Anti-cancer medicine

Challenge

            Patent Cliff

The Immunotherapy segment in the global Cancer Drug Market is expected to hold the highest market share during the forecast period. The growth can be attributed to growing areas within oncology R&D, high efficacy and fewer side effects and unique molecular level targeting.

On the other hand, Blood Cancer by the application is expected to grow at the highest CAGR during the year 2018-2023. Majorly due to growing number of blood cancer patient and the high cost of drugs used for the treatment of blood cancer.

Report: goo.gl/9GcCFX

Key Benefits for Stakeholders

Cancer Drug Manufacturers, Distributors and Retailers

Research and Consulting organization

Technology Standards Organizations, Forums, Alliances and Associations

End-use industries

Regulatory bodies, policy actors, and consumers.

By Products & Services

Immunotherapy (biologics therapy)        

Hormonal therapy         

Targeted therapy          

Chemotherapy  

Others              

By Application

Gastrointestinal cancer  

Blood cancer     

Prostate cancer 

Skin cancer      

Respiratory/lung cancer 

Breast cancer   

Other types of cancers

By Region

North America

Europe

Asia-Pacific

RoW

Key Market Players

  1. 1. Roche Holdings Inc.   
  2. 2. Johnson & Johnson    
  3. 3. Novartis AG  
  4. 4. Celgene        
  5. 5. Eli Lilly and Company
  6. 6. Pfizer           
  7. 7. Celgene Corporation  
  8. 8. Sanofi          
  9. 9. Merck & Co.  
  10. 10. Amgen Inc.

Read Report Overview with Full TOC at goo.gl/8rokE7

News From

Genesis Market InsightsGenesis Market Insights
Category: Market Research Publishers and RetailersCompany about: Genesis Market Insights (GMI), is a subsidiary of Genesis Management & Market Research Pvt.Ltd. (GMMR) having a strong experience both in primary and secondary market research serving small to large scale enterprises across the globe. Established in 1993, GMMR has become a recommended brand for Market Research for various international and MNC Corporations with its strong data foundation. With its exhaustive research capabilities, strong analytics services and in-house data validation tools, ...
This email address is being protected from spambots. You need JavaScript enabled to view it.